A prospective pharmacovigilance study to evaluate adverse effect profile of first line anti-tubercular drugs in newly diagnosed sputum positive patients


  • Akhil Agrawal Department of Pharmacology, SKNMC and GH, Narhe, Ambegaon, Pune, Maharashtra India
  • Uma A. Bhosale Department of Pharmacology, SKNMC and GH, Narhe, Ambegaon, Pune, Maharashtra India






Background: Tuberculosis (TB) continues to remain one of the most pressing health problems in India with highest TB burden country in the world. Anti-tubercular therapy (ATT) induced organ toxicities are potentially serious ADRs of first line ATT regimen. The underlying mechanism of ATT-induced ADRs especially hepatotoxicity and the factors predisposing to its incidence which is significantly high in Indians are not clearly understood. It's vital to emphasize on ATT induced ADRs as it has direct influence on therapeutic outcome; result in high dropout rate and potential to develop MDR/XDR cases. ADR monitoring help us to revise the treatment protocol thereby improve treatment adherence and therapeutic outcome. Objective of this study is therefore designed to explore and monitor ADRs of first line anti-TB drugs.

Methods: In this prospective observational study 60 TB patients (18-70 yrs) of either sex, newly sputum positive with normal parameters were included. Patients were followed up for six months aiming primarily to assess rate of ADRs and to identify preventable and potentially serious ADRs of anti-TB drugs. The ADRs of ATT on various organ systems (heart, kidney and liver), biochemical and haematological parameters were assessed and compared after 2 and 6 months; gender and age specific adverse events were also studied. Data obtained was analysed using student’s t-test of OpenEpi statistical software.

Results: Study clearly revealed that ATT exhibit significant increase in toxicity markers viz. liver enzymes (p<0.01), urea and creatinine (p<0.01), ESR (p<0.05) and PTINR (p<0.01), wherein decrease in Hb% (p<0.01) when compared to baseline.

Conclusions: ATT related ADRs is the major cause of dropouts and development of MDR/XDR cases. It's crucial to develop strategies to ameliorate ADRs both to improve the quality of patient care and to control TB safely. The data obtained from present study may be helpful in developing these effective strategies.


Srinivasan R, Ramya G. Adverse Drug Reaction-Causality Assessment. Int J Res Pharm Chem. 2011;1(3):606-12.

Merriam SB, Tisdell EJ. Qualitative Research: A Guide to Design and Implementation. John Wiley & Sons, 4th Edition; 24-Aug 2015.

Patel K, Kedia M, Bajpai D, Mehta S, Kshirsagar N, Gogtay N. Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study. BMC Clin Pharmacol. 2007;7(1):8.

Sinha K. Adverse drug reactions in tuberculosis patients due to directly observed treatment strategy therapy: Experience at an outpatient clinic of a teaching hospital in the city of Imphal, Manipur, India. 2013;1(2):12-5.

Kuchekar AB, Pujari RR, Kuchekar SB, Dhole SN. Psoriasis: A comprehensive review. Int J Pharm Life Sci. 2011;2(6):857-77.

Dean AG, Sullivan KM, Soe MM. Open Epi. Open Source Epidemiologic Statistics for Public Health. Version 2.3.1. 2013.

Balaji A, Rashmi K, Devinder MT. Scoring systems in acne vulgaris. Indian J Dermatol Venereol Leprol. 2009 May;75(3):323.

Marrow BB. Common Toxicity Criteria (CTC) Allergy/Immunology Auditory /Hearing. 1999;1998:1-35.

Noonan KA. the Impact of Chemotherapy-Induced Nausea and Vomiting. 2005;3(1):16-21.

McCombe A, Baguley D, Coles R, McKenna L, McKinney C, Windle-Taylor P. Guidelines for the grading of tinnitus severity: The results of a working group commissioned by the British Association of Otolaryngologists, Head and Neck Surgeons, 1999. Clin Otolaryngol Allied Sci. 2001;26(5):388-93.

National Institute of Cancer. Common Terminology Criteria for Adverse Events. 2010;2009:0-71.

Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis. Am J Respir Crit Care Med. 2003;167(11):1472-7.

Hassan MK, A ASP, Nagar G, Chas P, Bokaro D, City S, et al. Incidence of Adverse Drug Reaction Among the Tuberculosis Patients Treated Under Directly Observed Treatment Short course (DOTS) Regimen in North India. 2016;598-600.

Farazi A, Sofian M, Jabbariasl M, Keshavarz S. Adverse reactions to antituberculosis drugs in Iranian tuberculosis patients. Tuberculosis research and treatment. 2014 Nov 24;2014.

Gholami K, Kamali E, Mi SH. Evaluation of anti-tuberculosis induced adverse reactions in hospitalized patients. Pharm Pract. 2006;4(3):134-8.

Xiang Y, Ma L, Wu W, Liu W, Li Y, Zhu X, et al. The incidence of liver injury in uyghur patients treated for TB in Xinjiang Uyghur Autonomous Region, China, and its association with hepatic enzyme polymorphisms NAT2, CYP2E1, GSTM1 and GSTT1. PLoS One. 2014;9(1):1-8.

Abera W, Cheneke W, Abebe G. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: A cohort study. Int J Mycobacteriol. 2016;5(1):14-20.

Oliva VM, Cezário GAG, Cocato R. Pulmonary tuberculosis: hematology, serum biochemistry and the relation with the disease duration. J Venom Anim Toxins incl Trop Dis. 2008;14(1):71-81.

WW Y, CC L. Antituberculosis drugs and hepatotoxicity Deep Dyve. Respirology. 2006;11(6):699-707.

Sonika U, Kar P. Antituberculous drug-induced liver injury: current perspective. Trop Gastroenterol. 2011;32(3):167-74.

Patidar D, Rajput MS, Nirmal NP, Savitri W. Implementation and evaluation of adverse drug reaction monitoring system in a tertiary care teaching hospital in Mumbai, India. Interdiscip Toxicol. 2013;6(1):41-6.

Shu CC, Lee CH, Lee MC, Wang JY, Yu CJ, Lee LN. Hepatotoxicity due to first-line anti-tuberculosis drugs: A five-year experience in a Taiwan medical centre. Int J Tuberc Lung Dis. 2013;17(7):934-9.

Berlinger WG, Spector R. Adverse drug reactions in the elderly. Geriatrics. 1984;39(2):45-6,50-2,57-8.




How to Cite

Agrawal, A., & Bhosale, U. A. (2018). A prospective pharmacovigilance study to evaluate adverse effect profile of first line anti-tubercular drugs in newly diagnosed sputum positive patients. International Journal of Basic & Clinical Pharmacology, 7(2), 283–287. https://doi.org/10.18203/2319-2003.ijbcp20180099



Original Research Articles